Keros Therapeutics (KROS) vs Larimar Therapeutics (LRMR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Keros Therapeutics (KROS) has outperformed Larimar Therapeutics (LRMR) over the past year, losing 22.9% versus a loss of 52.7%. Over five years, KROS leads with a -72.5% price change compared with -84.5% for LRMR. Keros Therapeutics is the larger company by market cap ($211.4 million vs $206.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KROS | LRMR |
|---|---|---|
| Share price | $10.66 | $1.99 |
| Market cap | $211.36M | $206.21M |
| 1-day change | -3.96% | -0.25% |
| YTD return | -47.64% | -47.90% |
| 1-year return | -22.92% | -52.74% |
| 5-year return | -72.54% | -84.48% |
| EPS (TTM) | $-3.22 | $-1.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $243.86M | — |
| Net income (latest FY) | $87.01M | $-165.67M |
| Operating margin | 27.71% | — |
| Net margin | 35.68% | — |
| 52-week high | $22.55 | $6.42 |
| 52-week low | $9.69 | $1.92 |
| Distance from 52-week high | -52.73% | -69.08% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +86.02% | +625.44% |
| Average volume | 189.85K | 1.31M |
| Shares outstanding | 19.83M | 103.88M |
| Employees | 92 | 71 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KROS has outperformed LRMR by 29.8 percentage points over the past year.
About Keros Therapeutics
KROS stock →Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Larimar Therapeutics
LRMR stock →Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees
KROS vs LRMR FAQ
Which is bigger, Keros Therapeutics or Larimar Therapeutics?
Keros Therapeutics (KROS) is larger, with a market capitalization of $211.36M compared with $206.21M for Larimar Therapeutics (LRMR).
Which stock has performed better over the past year, KROS or LRMR?
KROS returned -22.92% over the past 12 months, compared with -52.74% for LRMR (price return, excluding dividends). Past performance does not predict future results.
Are Keros Therapeutics and Larimar Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.